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The SPOC1 cell, a novel goblet cell line derived from rat
trachea, was tested for its ability to exhibit regulated mucin
secretion in response to purinergic (P
#
) agonists. High-molecular-
mass glycoconjugates (HMMGs) purified by CsCl-density-gradi-
ent centrifugation had a buoyant density of 1.45 g}ml. The
purified HMMG material exhibited a single major band with an
apparent molecular mass of greater than 1000 kDa in SDS}
polyacrylamide gels stained with silver or blotted and stained
with soya-bean agglutinin. [$H]HMMG was resistant to
proteoglycan-degrading enzymes, but was susceptible to neura-
minidase. The HMMG was approx. 91% carbohydrate by
weight, and the glycosides were O-linked. The HMMG amino
acid composition was enriched in Ser and Thr (sum 27%). Thus
SPOC1-cell HMMG possess the characteristics of mucin. Mucin
secretion by SPOC1 cells, grown on permeable supports and
INTRODUCTION
Mucus formation in the airways results from the secretion of
high-molecular-mass mucin glycoproteins by specialized goblet
cells in the superficial epithelium and mucous cells in the
submucosal glands. Although mucin hypersecretion and goblet}
mucous cell metaplasia represent a major clinical manifestation
of chronic obstructive airways disease (cystic fibrosis, bronchi-
ectasis, chronic bronchitis, emphysema, and asthma) [1], very
little mechanistic information is available at the cellular and
molecular levels regarding the regulation of these processes. A
major effort over the past several years has been directed at the
development and study of primary cell cultures and epithelial
explants of the airway superficial epithelium [2,3]. From studies
with such experimental models, it is now known that mucin
secretion is regulated by purinergic agonists [2,4,5] and inflam-
matory mediators such as prostaglandin F
#
α [6] and platelet-
activating factor [7,8]. Attempts at further delineating the regu-
latory mechanisms involved have been generally hampered by
the heterocellular nature of most airway cell culture systems.
The recent development of the SPOC1 cell line [9,10] may be
a significant advancement in the availability of culture models
suitable for experimental efforts directed at studying the regu-
latory pathways governing mucin secretion. The SPOC1 cell was
derived from spontaneously immortalized rat tracheal epithelial
cell secondary cultures [9] ; the cells assume a goblet cell phenotype
when grown in tracheal xenografts [10]. The cell line has been
shown to be diploid with minor and stable alterations of
chromosomes 1, 3 and 6, and it has reduced requirements for
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perfused luminally, was stimulated by ATP, UTP and adenosine
5«-[γ-thio]triphosphate (100 µM) 4–5-fold over a baseline of
4 ng}min. The three dose–effect relations were nearly identical
(K
!.&
C 4 µM). SPOC1 cells grown on plastic and rat tracheal
epithelial primary cells responded similarly to ATP and}or UTP.
SPOC1 cells failed to respond to other purinergic agonists, either
luminally or serosally, and consequently seem to possess an
apical membrane P
#u
purinoceptor. SPOC1-cell total RNA was
probed for P
#u
purinoceptor mRNA. Using conserved primers
for both reverse transcriptase and PCR, a single band of the
predicted sizewas observed,which had a nucleotide base sequence
identical with the rat P
#u
purinoceptor mRNA. Thus SPOC1
cells secrete mucin under the control of a P
#u
purinoceptor; they
should prove useful in dissecting the associated cellular regulatory
pathways.
peptide growth factors [9]. The secretory granules of SPOC1 cells
grown in tracheal xenografts possess dense cores and are positive
for a rat tracheal mucin-specific monoclonal antibody (RTE11
mAb) [10]. When grown in culture, SPOC1 cells develop a
transepithelial electrical potential difference and resistance in-
dicative of a polarized epithelium [9], and the cultures immuno-
stain with RTE11 mAb and spontaneously secrete a glyco-
conjugate which reacts with the mAb [10]. Thus SPOC1 cells
possess a number of important characteristics of goblet cells.
In this study we first sought to determine the suitability of the
SPOC1 cell line for exploring the agonist regulation of goblet cell
mucin secretion. Whether the high-molecular-mass glycocon-
jugate (HMMG) secreted by SPOC1 cells is a mucin was tested
by purifying and characterizing the secretory product. That a P
#
purinoceptor regulates mucin secretion in the SPOC1 cell was
tested by challenging perfused cultures with hallmark nucleotide
agonists. Recent data for human airway epithelial explants
suggested that the specific identity of this goblet cell purinoceptor
is a P
#u
subtype [5]. Thus we also sought to use the pure
population of cells offered by the SPOC1 cell line to test this






Culture medium was purchased from Gibco}BRL (Gaithersburg,
MD, U.S.A.) and the supplements from Collaborative Research
(Bedford, MA, U.S.A.). The other chemicals used were purchased
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from Sigma Chemical Co. (St. Louis, MO, U.S.A.), unless
otherwise specified.
Cell culture
SPOC1 cells, passages 8–15, were seeded on Costar (Cambridge,
MA, U.S.A.) Transwell-COL 24 mm supports (TCol) at a density
of 120000 cells}support, in 12-well cluster plates at 40000
cells}well, or in 75 and 162 cm# tissue culture flasks (Costar T75
and T162) at 0.5¬10' or 1.0¬10' cells}flask respectively. The
cells were grown in an F12}Dulbecco’s modified Eagle’s medium
(DMEM)-based culture medium developed for primary cell
cultures of rat tracheal epithelial cells that has also been shown
to support the growth and differentiation of SPOC1 cells [10,13].
Briefly, the medium was supplemented with 30 mM Hepes,
6.5 mM -glutamine, 10 µg}ml insulin, 0.1 µg}ml hydrocorti-
sone, 0.1 µg}ml cholera toxin, 5 µg}ml transferrin, 50 µM phos-
phoethanolamine, 80 µM ethanolamine, 25 ng}ml epidermal
growth factor, 1% (v}v) bovine pituitary extract, 3 mg}ml BSA
(essentially globulin-free ; Sigma no. A7638), 50 units}ml peni-
cillin, and 50 µg}ml streptomycin. In addition, with the exception
of SPOC1 cells grown solely for passaging, the medium was
supplemented with 10 nM retinoic acid. The cultures were used
for experiments on days 6–12 after confluence, when cellular
Alcian Blue}periodic acid}Schiff reagent (AB}PAS)-positive ma-
terial was plentiful [10]. Primary cultures of rat tracheal epithelial
cells were prepared and grown on TCols as previously described
[13].
Histology
SPOC1 cell cultures grown on TCols were fixed in 2%
glutaraldehyde­2% paraformaldehyde, embedded in metha-
crylate, and sectioned to a thickness of 5 µm. The sections were
stainedwith Richardson’s stain [14] or by theAB}PAS procedure.
Purification of SPOC1-cell HMMG
HMMG was purified by dual CsCl-gradient centrifugation [15]
from material obtained from solubilized cells. SPOC1 cell cultures
grown for 6 days after confluence in T162 flasks were removed by
a 30 min exposure to PBS containing 10 mM EDTA (pH 7.4).
The cells were centrifuged (1500 g ; 10 min; 4 °C), and the pellet
was weighed and solubilized in 6 M guanidinium chloride
(Gibco}BRL) containing 5 mM EDTA and 0.1 mM PMSF.
After an overnight incubation with constant stirring at 4 °C, the
material was centrifuged at 1500 g for 30 min at 4 °C to remove
cellular debris. The solubilized material was prepared for density-
gradient centrifugation by adding CsCl (Fisher Scientific,
Pittsburgh, PA, U.S.A.), guanidinium chloride, and PBS to an
initial density of 1.40 g}ml and 4 M guanidinium chloride. The
solution was centrifuged for 3 days in a Beckman L7-55
ultracentrifuge equipped with a 50.2 Ti rotor at 150000 g
(36000 rev.}min) and 15 °C. Each tube was divided into 16
2.5 ml fractions which were weighed for density, and assessed for
DNA (A
#'!
) and sialic acid [16]. Sialic acid-positive fractions
were pooled and dialysed against 0.2 M guanidinium chloride in
PBS overnight at 4 °C. After adjusting the density of the solution
to 1.50 g}ml with CsCl, the material was centrifuged a second
time, as above, to separate mucins from residual DNA. The sialic
acid-containing fractions were pooled and dialysed against
deionized water. The HMMG content of this final solution was
determined by weighing the material obtained after drying a
known volume (85 °C; 36 h).
PAGE and lectin blotting
Samples of HMMG prepared in Laemmli buffer were subjected
to SDS}PAGE, under reducing conditions. HMMg (2–5 µg) was
loaded into the wells of 4–12% gradient polyacrylamide gels
(Novex, San Diego, CA, U.S.A.) and electrophoresed at 100 V
for 1 h. The resulting gels were stained with silver [17] (Silver
Stain Plut Kit ; Bio-Rad) or PAS [18], or the samples therein were
transferred to a poly(vinylidene difluoride) membrane (Immo-
bilon-P, Millipore, Bedford, MA, U.S.A.) at 25 °C for 2 h under
a constant current of 200 mA in transfer buffer (192 mM glycine,
25 mM Tris, 20% methanol, pH 8.3). Blotted membranes were
washed in PBS­0.05% Tween-20, blocked by incubation in
0.1% gelatin in PBS overnight, and then incubated in 0.1 µg}ml
horseradish peroxidase-conjugated soya-bean agglutinin (SBA)
for 1 h at room temperature. After being washed, the blots were
developed with an enhanced chemiluminescence kit (Amersham,
Arlington Heights, IL, U.S.A.).
[3H]HMMG labelling, enzymic digestion and Sepharose CL-4B
column chromatography
SPOC1 cell cultures grown on plastic were exposed to
[$H]glucosamine (1–5 µCi}ml; specific radioactivity 40 Ci}mmol)
for 24 h. After removal of the label and a thorough wash with
F12}DMEM, the cells were either solubilized in guanidinium
chloride and the HMMG was purified by density-gradient
centrifugation, or exposed to adenosine 5«-[γ-thio]guanosine
(ATP[S]) (100 µM) for 1 h (see Figure 7) and the medium
collected, centrifuged at 1500 g, and the supernatant stored at
4 °C. These materials were subjected to enzymic digestion in a
0.1 M sodium acetate or Tris}acetate buffer with its pH and
[Ca#+] optimally adjusted for the respective enzyme, as follows:
hyaluronidase, 10 units}ml, pH 6.1, for 20 h at 37 °C; heparinase
III, 5 units}ml, pH 7.0, 1 mM Ca#+, for 5 h at 42 °C;
chondroitinase ABC, 0.2 unit}ml, pH 7.4, for 5 h at 37 °C; and
neuraminidase, 0.6 unit}ml, pH 7.4 for 4 h at 40 °C. Each enzyme
was obtained fresh from the manufacturer and used immediately.
Each digestion was stopped by boiling, the sample was cooled to
room temperature and diluted with an equal volume of 2-fold
concentrated PBS. A 1 ml portion of each sample was chroma-
tographed at 0.33 ml}min on a Sepharose CL-4B (Pharmacia}
LKB, Uppsala, Sweden) column (1 cm¬50 cm). In all, 45 1 ml
fractions were collected and aliquots thereof were mixed with
5 ml of Scintiverse (Fisher) and assessed for radioactivity in a
Wallac 1410 (Gaithersburg, MD, U.S.A.) liquid-scintillation
counter.
Thiol reduction and alkylation, β-elimination and proteolysis
Culture medium containing [$H]HMMG was recovered from
SPOC1 cells that had been grown on plastic, labelled overnight
with [$H]glucosamine, washed and exposed to ATP[S] as above.
The susceptibility of the [$H]HMMG to disulphide bond re-
duction was tested by incubating the material in 2.5% (v}v) 2-
mercaptoethanol}1% SDS for 5 min at 100 °C, pH 8.6. The
material was then alkylated by an overnight incubation with
0.4 M iodoacetamide in the dark at 4 °C, following which it was
exhaustively dialysed against distilled water and analysed by
Sepharose CL-4B chromatography. The presence of O-glycosides
in the [$H]HMMG was tested by (non-reductive) β-elimination:
the material was incubated in 50 mM NaOH at 45 °C for 16 h,
and then neutralized with acetic acid and chromatographed on
Sepharose CL-4B. The susceptibility of the [$H]HMMG to
proteolysis was tested by digesting [$H]HMMG with trypsin
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Figure 1 Perfusion of SPOC1 cells grown on permeable supports
For SPOC1 cell cultures grown on TCol inserts, the ‘ perfusion plug ’ depicted, fabricated from
Delrin, was pressed into the cup-like portion of the insert, such that the O-ring seal created a
closed compartment on the luminal side of the culture. Dotted arrows indicate the perfusion
path. There was a nominal 2 mm clearance between the bottom of the plug and the permeable
support.
(100 µg}ml) for 5 h at 37 °C after dialysis against a 0.1 M
Tris}HCl buffer, pH 8.0. Both native and reduced}alkylated
[$H]HMMG preparations were so digested, after which the
materials were boiled to inactivate the protease and analysed by
Sepharose CL-4B chromatography.
Protein determinations
The protein content of purified SPOC1 HMMG was determined
after deglycosylation of a 100 µg sample by β-elimination
(above), followed by a 24 h dialysis (10 kDa cut-off) against
distilled water. The protein content of the material was then
determined in parallel samples using the bicinchoninic acid
procedure (BCA Protein Assay kit, Pierce Chemical Co.,
Rockford, IL, U.S.A.) and the procedure of Lowry et al. [19], in
each case using BSA as the standard.
Amino acid analysis
Samples were hydrolysed, after flushing with N
#
, in 6 M HCl
under vacuum at 115 °C for 24 h. The hydrolysates were analysed
for their amino acid compositions on a Varian 5560 liquid
chromatograph configured as an amino acid analyser (AA911
column; Interaction), using ninhydrin with colour development
in a stainless-steel reaction coil. Temperature was maintained at
135³0.05 °C with a thermostatically controlled silicone oil bath.
The ninhydrin colour was monitored at 570 nm, except for
proline which was determined at 440 nm.
SPOC1 cell perfusion and enzyme-linked lectin assay (ELLA)
SPOC1 cells grown on TCols were perfused luminally using the
‘perfusion plug’ depicted in Figure 1. TCols, with perfusion
plugs inserted, were placed in a six-well cluster plate containing
F12}DMEM. A similar perfusion plug was used for SPOC1 cells
grown in 12-well cluster plates. In both cases, the cluster plates
were placed in a water bath at 35 °C, and the affluent perfusion
tubing was submerged to preheat the perfusion fluid
(F12}DMEM). The cultures were perfused using a multichannel
peristaltic pump (Masterflex; Cole Parmer, Chicago, IL, U.S.A.)
at 0.2 ml}min, and the perfusate was collected with a multi-
channel fraction collector (IC-200; Buchler Instruments, Lenexa,





, and the water bath was covered and
vigorously gassed with the same mixture; the pH of the perfusate
was 7.4 at its entry into and exit from the chamber. Luminal
Figure 2 Standard curve for an ELLA using SBA and purified SPOC1 mucin
The ELLA utilized horseradish peroxidase-conjugated SBA and purified SPOC1 mucin (ng dry
wt/ml) and were performed on 96-well microtitre plates. The data are expressed as
means³S.E.M. (n ¯ 3).
addition of agonists was achieved by quickly shifting the afferent
tubing to a new reservoir. Serosal addition of agonists to cultures
grown on TCols was achieved by direct addition to the medium
bathing the bottom of the culture.
Collected fractions were assessed for mucin content by ELLA.
Samples of volume 100 µl were bound to 96-well high-binding
microtitre plates (Costar no. 3590) overnight at 4 °C, or for 2 h
at 37 °C. The plates were washed with PBS containing 0.05%
Tween 20 and 0.02% thimerosol, and incubated with 1–5 µg}ml
horseradish peroxidase-conjugated SBA for 1 h at 37 °C. The
plates were washed and developed by incubating in them 0.04%
(w}v) substrate (o-phenylenediamine in 0.0175 M citrate}












was determined in a microtitre plate reader (Dynatech
model MR5000, Chantilly, VA, U.S.A.). Absorbance was con-
verted into ng of mucin from a standard curve (Figure 2) using
purified SPOC1 HMMG (see Figure 4, right), one of which was
constructed for each microtitre plate assayed.
Reverse transcriptase (RT)-PCR
RNA was isolated from SPOC1 cells, rat lung and rat colon by
CsCl-density-gradient centrifugation [20]. Primers for the RT
reaction and PCR were designed against regions of the P
#u
purinoceptor gene which are highly conserved between human
[12] and mouse [11]. A cocktail, 1 µM each, of three gene-specific
primers (CTCCTCTGAGCTAAGTCCATCGTGC, GGGCT-
CTGCTGTGTCCTCTCTGAGCC and GGAGTCCTGCTA-
CTCTTGGGACAG) was used for the RT reaction, using 8 µg
of total RNA. The RT reaction was followed immediately by 35
cycles of hot-start PCR, as per the kit instructions (cDNA Cycle
Kit ; Invitrogen, San Diego, CA, U.S.A.). The forward and
reverse primers had the following respective sequences : CTGG-
AATAGCACCATCAATGG and GAAGGTGGTGGACAA-
AGTAGAGCAC. The PCR products were analysed by ethidium
bromide staining after electrophoresis in a 2% agarose gel.
Fragments were purified from positive bands on Qiaex beads
(Qiagen Corporation, Chatsworth, CA, U.S.A.), and were sub-
cloned into the T-tailed pCR vector (Invitrogen). Minipreps of
transformed colonies were prescreened by EcoRI digestion to
verify the presence and size of the inserts, and were sequenced
with the Sequenase kit (United States Biochemical, Cleveland,
946 L. H. Abdullah and others
OH, U.S.A.). Sequence data were analysed with the Genetics




As shown previously by Randell et al. [10], SPOC1 cells grown
for 6–12 days after confluence of TCols possess a multilayered
morphology (Figure 3). A layer of cuboidal cells resides along
the substratum with one to two layers lying above. Only the cells
in these outer layers contain AB}PAS-positive material in their
apical poles ; cells in the basal layer are AB}PAS-negative.
HMMG purification
The HMMG from solubilized SPOC1 cells was localized as a
well-formed peak of sialic acid content after the first density-
gradient centrifugation (Figure 4). Four sialic acid-positive
fractions were pooled as indicated, and, after dialysis against
0.2 M guanidinium chloride, the material was subjected to a
Figure 3 Light microscopy of SPOC1 cells grown on TCols
Sections (8 µm thick) of specimens 6 days after confluence were stained for general
morphology with Richardson’s stain (A) or for carbohydrate-bearing structures with AB/PAS
stain (B).
Figure 4 Isopycnic density-gradient centrifugation of SPOC1 HMMG in CsCl
Left, results of the first centrifugation, with 4 M guanidinium chloride and the starting density
adjusted with CsCl to 1.40 g/ml. Right, results of the second centrifugation : 0.2 M guanidinium
chloride and starting density, 1.50 g/ml. The 2.5 ml fractions were assessed for density (+),
DNA (A260 ; _) and sialic acid (A630 ; D). The horizontal bars in each panel indicate fractions
pooled for subsequent analysis or use.
second density-gradient centrifugation. This second centri-
fugation yielded a sharp peak in sialic acid content that was well
separated from DNA. The densities of the two pooled fractions
were 1.46 and 1.44 g}ml. This purified HMMG was dialysed
exhaustively against distilled water, and subjected to further
analysis. The results of three such purifications using different
passages of cells were similar, yielding 0.79³0.09 mg dry weight
of HMMG}g wet weight of SPOC1 cells (mean³S.D.).
SDS/PAGE analysis of SPOC1 HMMG
The purified HMMG was analysed by electrophoresis in 4–12%
polyacrylamide gradient gels. Figure 5 shows the results of one
analysis in which the purified cell-associated HMMG was
compared with the material released into the cell culture medium
after a 30 min maximal stimulation with ATP[S] (100 µM; see
below). Duplicate lanes were silver-stained, or blotted and probed
with the N-acetylgalactosamine-specific lectin, SBA. The purified
cell-associated HMMG resolved as two bands in both staining
protocols with apparent molecular masses greater than 1000 kDa
and 265 kDa. The former was contained entirely within the
stacking gel. In the SBA blot, this band stained intensely relative
to the weakly staining 265 kDa band. In the silver-stained gel, by
contrast, the two bands had approximately the same staining
intensity. The strong SBA, but weak silver, staining of the "
1000 kDa band is consistent with the material being a gly-
coprotein, i.e. extensive carbohydrate linkages shield the inner
apoprotein from the silver stain, but interact strongly with the
lectin. In support of this notion, in gels stained with PAS reagent,
only the " 1000 kDa band was identifiable (results not shown).
Culture medium from SPOC1 cells stimulated with ATP[S] for
30 min and applied to the gel neat contained the " 1000 kDa
material in both the silver-stained gel and the SBA blot. The
265 kDa band did not resolve well in the SBA blot, and in the
silver-stained gel numerous additional bands were apparent at
molecular masses of 265 kDa and below. From these analyses, it
appears that HMMG material is released from SPOC1 cells by
solubilization that has a mobility on SDS}PAGE similar to the
material secreted by the cells. Importantly, of the numerous
proteins secreted by SPOC1 cells only the HMMG material
interacts with SBA.
Enzymic digestion, thiol reduction and β-elimination of HMMG, and
Sepharose CL-4B column chromatography
To determine whether the purified HMMG material and other
materials released into culture medium were comprised of
proteoglycan or mucin, SPOC1 cells were labelled by exposure to
[$H]glucosamine and the materials collected were exposed to
enzymes that hydrolyse specific carbohydrate linkages. Figure
6(A) shows the results for cell-associated [$H]HMMG obtained
by solubilization of SPOC1 cells and purified by density-gradient
centrifugation. The profile of undigested HMMG (Figure 6A,
top) shows that nearly all of the radioactivity was eluted in the
void volume (V
!
) of the column, as expected. In addition,
digestion of the material with neuraminidase caused a significant
shift in the elution profile, such that one-third to one-half of the
total radioactivity was eluted at volumes greater than V
O
,
including a large symmetrical peak at the total column volume
(V
T
). This result signified that terminal sialic acid was labelled by
the exposure to [$H]glucosamine and was released by neur-
aminidase. None of the other enzymes tested had significant
effects on the purified [$H]HMMG: the radioactivity of material
exposed to heparinase III, hyaluronidase and chondroitinase
ABC was eluted in V
O
, similar to the control (Figure 6A,
bottom).
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Figure 5 Electrophoresis of SPOC1 HMMG in 4–12% gradient poly-
acrylamide gels under reducing conditions
Duplicate lanes of a gel were either silver-stained (left) or blotted and probed with the SBA lectin
(right). The outer lanes in each case contained HMMG (mucin) purified by density-gradient
centrifugation, whereas the inner lanes contained culture medium from SPOC1 cells stimulated
with ATP[S] (ATPγS). Positions of molecular-mass markers (kDa) are indicated.
The HMMG material released into the culture medium by
ATP[S]-stimulated SPOC1 cells was also subjected to enzymic
digestion. As shown in Figure 6(B), the undigested control
Figure 6 Sepharose CL-4B column chromatography
(A) Elution profiles of [3H]glucosamine-labelled HMMG purified by density-gradient centrifugation. Top, control, or untreated, mucin and mucin digested with neuraminidase ; bottom, mucins digested
with proteoglycan-degrading enzymes. (B) and (C) Elution profiles of culture medium from [3H]glucosamine-labelled cells stimulated with ATP[S] ATPγS. (B) Control medium and medium
digested with proteoglycan-degrading enzymes ; (C) control medium and medium after thiol reduction and alkylation or after β-elimination. Note that HMMG challenged with proteoglycan-degrading
enzymes (A, bottom, and B) was boiled in a manner similar to that subjected to thiol reduction (C). The column was repacked for each experiment.





















* Cys was measured as cystine ; thus this value represents a minimum of 22 mol of Cys
(half)/1000 residues.
medium yielded an elution profile similar to that seen for purified
HMMG (Figure 6A), with the exception that a secondary peak
at V
T
was present which presumably represents residual [$H]glu-
cosamine. There was no discernible effect on the secreted HMMG
of digestion with heparinase III, hyaluronidase and chond-
roitinase ABC: the elution profiles from these digestions es-
sentially overlaid that of the control.
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Figure 7 Effects of purinergic stimulation on mucin secretion by SPOC1
cells
Left, time course of the response to ATP (100 µM) by SPOC1 cells grown on TCols. The
cultures were perfused luminally with F12/DMEM, fractions were collected at 5 min intervals,
and ATP was applied to the perfusion bath at the time indicated by the arrow. The delay in the
mucin-secretory response is due largely to the perfusion system. Right, dose–effect relations
for three purinergic agonists, ATP (E), ATP[S] (+) and UTP (*). The data are presented
as the suprabasal mucin-secretory response integrated over a 1 h exposure to agonist. In both
panels, each point is represented as the mean³S.E.M. of six SPOC1 cell cultures from two
passages.
As a final test for the presence of proteoglycan materials
released from ATP[S]-stimulated SPOC1 cells, the medium
[$H]HMMG material isolated in the V
O
fractions was subjected
to CsCl-density-gradient centrifugation. This analysis yielded a
symmetrical peak of radioactivity centring on a density of
1.44 g}ml where mucin would be expected to distribute. No
other peak of radioactivity was located within the gradient
(results not shown).
Native mucins are generally extensively cross-linked via di-
sulphide bonds formed between cysteine residues localized to the
N- and C-termini of the macromolecules [21–23]. The presence of
such disulphide linkages in SPOC1 HMMG was tested by thiol
reduction and alkylation followed by chromatography on
Sepharose CL-4B. As shown in Figure 6(C), the material
subjected to this procedure was eluted from the column over a
wide range of included volumes, indicating that thiol reduction
and alkylation successfully cleared disulphide linkages between
individual HMMG molecules.
To determine whether the HMMG contained O-glycosidic
linkages as would be expected of mucins, material labelled with
[$H]glucosamine was subjected to non-reductive-β-elimination.
Figure 6(C) shows that this procedure caused essentially all of
the labelled material to be eluted from the column in a wide
symmetrical peak centred on a volume near V
T
. This result
indicates that most of the carbohydrate associated with the
HMMG is O-linked.
Digestion of [$H]HMMG with trypsin, whether in the native
form or after reduction and alkylation, yielded a broad hetero-
disperse population of glycopeptides, as judged by Sepharose
CL-4B chromatography (results not shown). For reduced and
alkylated mucins, trypsin digestion shifted all of the radioactivity
out of the void volume, whereas with control mucins approx.
10% of the material was eluted in the void volume. These results
were similar to those obtained by others with a wide variety of
purified mucins [24].
Figure 8 Effects of UTP on RTE primary cell cultures
Left, time course of the response to the addition of UTP (100 µM) to the luminal perfusion fluid
of TCol cultures. UTP was added at the time indicated by the arrow. Right, dose–effect relations
for UTP on the suprabasal integrated mucin-secretory response. In each panel, each point is
represented as the mean³S.E.M. of six cultures from two different preparations.
Protein content of SPOC1 HMMG
The protein content of SPOC1 HMMG was determined using
two independent procedures after deglycosylation of a 100 µg
sample of purified material. The value yielded by the BCA
procedure was 9.4 µg of protein, and that by the Lowry procedure
was 9.1 µg of protein. Hence, by these measures, the protein
content of SPOC1 HMMG is approximately 9%, leaving the
carbohydrate content to be approximately 91%.
Amino acid analysis
HMMG purified by density-gradient centrifugation was assessed
for amino acid composition. Relative to the 5% content expected
from a purely random distribution of each amino acid, the
results (Table 1) indicated that the material was rich in Ser and
Thr, with the two residues accounting for 27% of the total
amino acids. The HMMG was also enriched in Gly and Glx, and
was deficient in Met, Cys, Tyr. Since it is likely that only the
disulphide-bonded form of Cys (cysteine) survived the acid
hydrolysis of the HMMG preparatory to amino acid composition
analysis, the 11 mol of Cys}1000 residues reported represents a
minimum of 22 mol of cysteine}1000 residues.
As discussed fully below, the HMMG secreted by SPOC1 cells
has the characteristics expected of a mucin, and shall hereafter be
referenced as such.
Purinergic stimulation of mucin secretion
In SPOC1 cells grown on TCols and perfused luminally with
F12}DMEM, a basal release of mucin was observed at approx.
4 ng}ml. On luminal exposure to a maximal dose of ATP
(100 µM), mucin secretion was stimulated 4–5-fold over a period
of 20–30 min (Figure 7). Histological analysis of cultures after
stimulation revealed that the overall appearance of the SPOC1
cells was nominally unchanged compared with non-stimulated
controls (results not shown). That the relatively slow onset of the
mucin-secretory response is not an artifact of the SPOC1 cell line
was tested by conducting comparable experiments on rat tracheal
epithelial (RTE) primary cell cultures. The baseline rates of
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Figure 9 Response of SPOC1 cells grown on plastic to purinergic agonists
The SPOC1 cells were grown in 12-well cluster plates and perfused in a study similar to one
shown in Figure 7. Left, either ATP or UTP (100 µM) was added at the arrow. Right, dose–effect
relations for ATP and UTP on the suprabasal integrated mucin-secretory response. In each
panel, each point is the mean³S.E.M. and represents six cultures from two different passages.
mucin secretion by the primary cell cultures from two different
preparations were 5.0³0.3 and 23.1³0.8 ng}min. Because of
this difference, the data were expressed relative to the mean
baseline rate. As shown in Figure 8, the time course of the
relative secretory response of the primary cell cultures to UTP
was very similar to the response of SPOC1 cells to ATP, and
there was about a 2.5-fold stimulation over baseline.
ATP, ATP[S] and UTP were all effective secretagogues for
mucin secretion by SPOC1 cells. As Figure 7 shows, the
dose–effect relationships for these agonists were virtually ident-
ical, and yielded an apparent K
!.&
for the mucin-secretory
response of approx. 4 µM. The apparent affinity of UTP in
eliciting mucin secretion by RTA primary cell cultures was also
about 4 µM. The effectiveness of ATP[S] and UTP in eliciting
mucin secretion by SPOC1 and RTE primary cell cultures is
consistent with their possession of an apical membrane P
#u
purinoceptor. To test whether other apical membrane purino-
ceptors are expressed by SPOC1 cells, TCol cultures were






respectively [25,26]. These agonists had no effect on mucin
release, and the cultures responded normally to a subsequent
challenge with UTP (results not shown).
Whether a permeable support was essential for the support of
regulated SPOC1 cell mucin secretion was tested by perfusing
cultures grown on plastic (12-well plates). Figure 9 shows the
results of two studies in which cultures were challenged with
ATP or UTP. In each case, the cells responded to the purinergic
challenge with approximately the same time course and apparent
affinity as observed for SPOC1 cultures grownonTCols (compare
with Figure 7).
In other experiments, the response of SPOC1 TCol cultures to
serosal applications of purinergic agonists was assessed. No
response was observed, in multiple experiments (n& 3), with
100 µM adenosine, ATP, UTP, ATP[S] or 2-methylthio-ATP
(results not shown). In each experiment, after the serosal test
challenge, the cultures were challenged luminally with ATP or
UTP, and in each case a normal mucin-secretory response was
elicited. It therefore appears that P
#u
purinoceptors are selectively
Figure 10 Ethidium bromide staining of products from RT-PCR for the P2u
purinoceptor
Total RNA from fresh colon and lung and from SPOC1 cells was subjected to an RT reaction with
primers specific to human P2u purinoceptor mRNA and then to PCR with primers to conserved
regions of the gene. One-half of the resulting DNA products from each reaction were applied
to the 2% agarose gel shown.
localized to the apical membrane in SPOC1 cells, and that other
types of purinoceptor are absent from both membranes.
Identification of P2u purinoceptor
The data presented above and from other studies [2,4,5] suggest
that the P
#u
purinoceptor is the receptor that accounts for the
response of goblet cells to purinergic agonists. To test this
possibility, RT-PCR was used to probe SPOC1 cell total RNA
for the presence of the P
#u
purinoceptor. A single band of the
predicted size (502 bp) was obtained for both SPOC1 cells and
fresh rat lung (Figure 10), with the SPOC1 band being much
more intense than that from lung. Rat colon total RNA was
negative for P
#u
purinoceptor mRNA, but an identical sample
tested for another mRNA as part of another study was positive
(CFTR; results not shown). The PCR product from SPOC1
RNA was subcloned and the partial nucleotide base sequence (80






The HMMG purified from solubilized SPOC1 cells can be
identified by multiple criteria as a mucin [21–23,28,29]. The
material (i) possesses a molecular mass greater than 1000 kDa
(Figure 5), (ii) is within the range of other mucins with a buoyant
density of 1.45 g}ml (Figure 4), (iii) reacts positively with PAS
and has an affinity for a lectin (SBA) that binds N-
acetylgalactosamine, an amino sugar characteristic of mucins
(Figure 5), (iv) is susceptible to digestion by neuraminidase and
resistant to proteoglycan-degrading enzymes (Figures 6A and
6B), (v) contains intermolecular disulphide bonds which are
responsible for the non-reduced material being eluted in the void
volume of a Sepharose CL-4B column (Figure 6C), (vi) is
primarily carbohydrate in content (91%) which is O-linked to
the apomucin protein (Figure 6C) and (vii) has an amino acid
composition enriched in Thr, Ser and Gly (Table 1). Thus
SPOC1 cells not only possess the overall appearance of goblet
cells when grown in tracheal xenografts and stain with AB}PAS
and RTE11 mAb when grown in culture [10], but they also
contain HMMGs having the biochemical characteristics of
mucin. This material also appears to be secreted by SPOC1 cells
under the stimulation of purinergic agonists since the high-
molecular-mass material detected in the culture medium bathing
stimulated cells, when compared with cell-associated mucin, has
950 L. H. Abdullah and others
similar (i) silver- and SBA-staining patterns on SDS}PAGE
(Figure 5), (ii) resistances to proteoglycan-degrading enzymes
Figure 6) and (iii) buoyant densities (1.44 and 1.45 g}ml re-
spectively.
We note that in the chromatogram in Figure 6(C) thiol
reduction and alkylation of culture medium harvested from
SPOC1 cells stimulated with ATP[S] caused the mucins therein
to be eluted over a broad range of void and included volumes. In
the SBA blot of the same material (Figure 5), however, most of
the lectin-positive material was present as a narrow zone in the
stacking gel. At least two potential explanations exist for this
apparent inconsistency. The Sepharose CL-4B column and the
4–12% gradient gel used for electrophoresis do not have identical
separation profiles, which may have resulted in a relatively
compressed pattern on the gel. The SBA lectin used to probe the
blot for HMMG also may detect only a subset of the total
carbohydrate materials labelled with [$H]glucosamine. Were the
ratio of lectin-detectable to total carbohydrate residues to differ
in the mucin species of different molecular mass that resulted
from thiol reduction, the two means of detection would have
yielded different signal profiles.
Three characteristics of the purified SPOC1 mucin and}or its
secretion merit comment. First, SDS}PAGE analysis of mucin
yielded both a silver- and an SBA-stained band of protein with
an apparent molecular mass of 265 kDa, whereas the Sepharose
CL-4B column elution profile of purified radiolabelled mucin





likely explanation of this difference is that the PAGE was
performed under reducing conditions, and that during non-
reducing conditions of the CL-4B column chromatography the
265 kDa protein remained associated with mucin, presumably
through disulphide linkages. This notion is supported by the
observation (Figure 6C) that thiol reduction and alkylation
caused the HMMG to be eluted from a CL-4B column over a
wide range of included volumes. It is possible that this extraneous
265 kDa band is a cross-linking glycoprotein, similar to the
putative ‘ link’ glycopeptide that has been hypothesized for
gastrointestinal tract mucins ; however, it is more than twice the
size of the 118 kDa ‘ link’ glycoprotein [30]. Its size (265 kDa) is
within the range that might be expected for a mucin aproprotein.
Thus a poorly glycosylated mucin that exists as a minor
component of the secretory product is another possibility. For
the purposes of this study, the quantity of the material is too
small relative to that comprising the " 1000 kDa mucin (Figure
5) to compromise the conclusions made herein.
Second, from other studies on cultured cells, proteoglycan
materials would not have been an unexpected component of the
culturemedium removed from SPOC1 cells [29]. Our observation,
however, was the apparent absence of such material : not only
was the medium HMMG from ATP[S]-stimulated cells resistant
to digestion by proteoglycan-degrading enzymes (Figure 6C),
but the void-volume material resolved as a single peak with a
buoyant density of 1.44 g}ml by density-gradient ultracentri-
fugation (results not shown). A likely explanation for the
apparent lack of proteoglycans in the culture medium is that
these proteins would be expected to be part of the extracellular
adherence mechanism. Thus such proteoglycans that escaped to
the medium would probably have been removed by the thorough
washing applied to the cultures before the 30 min incubation
with ATP[S]. The apparent absence of proteoglycans from the
HMMG material is therefore most likely due to its absence from
the secretory mucin pool rather than to a complete lack of
proteoglycan secretion by SPOC1 cells. One beneficial effect of
the lack of HMMGs other than mucin in the secretory product
released by purinergic agonists was that it allowed an un-
ambiguous and highly sensitive assay for mucin to be developed,
using SBA as the binding agent in an ELLA (Figure 2).
Third, the amino acid composition of SPOC1 mucin (Table 1)
is similar to that of other mucins in containing relatively high
amounts of Ser and Thr [22,28] ; however, it is significantly
different from the composition of mucin secreted by RTE primary
cultures [13]. Specifically, SPOC1 mucin has less Pro and Gly,
and more Thr and Glx, than is found in HMMG from RTE
primary cultures. One possible reason for these differences is that
different techniques were used for the purification and de-
termination of the amino acid composition of the mucin studied.
Also, the high Gly content of RTE primary mucin may be due to
an overestimation by interference with glucosamine, whereas we
corrected for this possibility. A more likely reason is that RTE
primary and SPOC1 cells express different HMMGs; the rat
airways are likely to secrete a variety of mucins, of which RTE
primary and SPOC1 cells may express different subsets. Lastly,
non-mucin HMMG may be expressed and secreted by RTE
primary cells [13]. In either case, because of the difficulties
inherent in the characterization of mucins, the apparent dif-
ferences between the secretory products of SPOC1 and RTE
primary cells are most likely to be resolved after the genes
encoding the secreted HMMGs are identified.
Purinergic regulation of mucin secretion
The mucin-secretory responses of perfused SPOC1 and RTE
primary cell cultures to the purinergic agonists ATP, ATP[S] and
UTP were similar (Figures 7 and 8). In each case, mucin secretion
was stimulated over a period of 20–30 min with 4–5 and 2.5-fold
stimulations over baseline rates of secretion respectively. In
native goblet cells observed by video microscopy, we have
observed mucin granule exocytosis to commence essentially
immediately on ATP stimulation [2]. One possible reason for the
apparent slow onset of secretion when assessed instead by
biochemical determination of mucins released into a perfusate is
that time is necessary for the mucins to hydrate and solubilize
after exocytosis [31]. To allow for this possibility, the dose–effect
relationships for purinergic stimulation of mucin secretion were
determined as the integrated response, above baseline, over a
period of 60 min (Figures 7–9).
Both the pattern of responses by SPOC1 and RTE primary cell
cultures to, and their affinities for, hallmark purinergic agonists
indicated a P
#u
purinoceptor [25,26]. In both cases, the cells
responded with similar time courses and kinetics to ATP and
UTP (Figures 7 and 8). SPOC1 cells in addition responded
similarly to ATP[S], but did not respond to either the P
#y
purinoceptor agonist, 2 methylthio-ATP, or the P
"
agonist,
adenosine. The apparent affinities for ATP, ATP[S] and UTP in
eliciting a mucin-secretory response were in the low micromolar
range, as appropriate for P
#u
purinoceptor agonists [25,26]. In
their pattern of agonist-induced responses, SPOC1 and RTE
primary cells are similar to goblet cells in primary cultures of
hamster tracheal epithelial cells [4] and those in explanted native
human and canine superficial epithelia [2,5]. In addition, SPOC1
cells are similar to human and canine native goblet cells in not
responding to luminal challenges with other purinergic agonists
[2,5]. Thus by simple pharmacological criteria both the SPOC1
and RTE primary cells possess an apical membrane P
#u
purino-
ceptor, and the SPOC1 cell apparently possesses no other apical
membrane purinoceptor.
An important practical observation was that SPOC1 cells
respond to purinergic agonists with a stimulation of mucin
secretion equally well whether grown on permeable supports
(TCols) or plastic (compare Figures 7 and 8). There were no
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functional differences between cells grown on the two substrata
in either the time course of the development of the mucin-
secretory response to, or the apparent affinity of, luminal
challenges with purinergic agonists. This observation is in distinct
contrast with primary cell cultures that achieve an acceptable
degree of secretory cell differentiation only when grown on
permeable supports and generally on a substratum of collagen or
other extracellular matrix protein [3,13,32].
SPOC1 cells differ from native goblet cells in lacking the ability
to respond to serosal purinergic agonists. We have shown that
goblet cells in native explanted epithelium respond by mucin
granule exocytosis to serosal challenges with ATP, the non-
hydrolysable 5«-adenosine imidodiphosphate, ADP and adeno-
sine [2]. Of the many possible scenarios that could explain these
differences, the only one in which SPOC1 and native goblet cells
possess identical regulatory pathways holds the serosal responses
in native tissues to be indirect and due to a primary stimulation
of luminally directed ATP secretion by other cells in the
epithelium. This local luminal ATP secretion would then stimu-





The extracellular actions of ATP in the non-vascular aspect of
the lung were first appreciated for the stimulation of surfactant
secretion by alveolar type II cells [33], of transepithelial ion and
fluid transport in the airways [34,35], and of goblet cell mucin
secretion [2,4,5]. The pharmacology of these responses proved
not to match those of known purinoceptors, however, but
instead indicated a novel receptor at which ATP and UTP were
equipotent [34,36]. The P
#u
purinoceptor, originally cloned and
sequenced from mouse neuroblastoma cells [11], allowed the
subsequent cloning of the gene from a human airway cell line [12]
and rat alveolar type II cells [27]. The P
#u
purinoceptors from the
three species share a 97% identity and are expressed in a wide
variety of tissues. The finding in this study that a P
#u
purinoceptor
mRNA is expressed in SPOC1 cells (Figure 10) is fully consistent
with the pharmacology of purinergic stimulation of mucin
secretion by globlet cells, namely that the mucin-secretory
response is stimulated equally by ATP and UTP (Figure 7;
[2,4,5]). No purinoceptor has been identified at the protein level
in any cell type, so this demonstration in goblet cells must await
the necessary reagents. The P
#u
purinoceptor is the first receptor
to be specifically identified at the mRNA level in a mucin-
secreting cell of any type.
The SPOC1 cell line
As discussed above, SPOC1 cells grown in culture possess many
physiological and pharmacological aspects relevant to ‘normal ’
goblet cell function. On the other hand, the cells do not exhibit
the morphological features of typical goblet cells, except when
grown in tracheal xenografts [10]. SPOC1 cells in culture exhibit
AB}PAS-positive material in the other cell layers, but they are
cuboidal and express keratins that are normally found in other
epithelial cell types. They also do not express K18 which is
characteristically expressed in columnar epithelial cells [9]. None-
theless, in providing a relatively pure population of secretory
cells, for which a basal-like cell is the only major ‘contaminant’,
the SPOC1 cell may offer a unique opportunity for dissection of
the regulatory pathways controlling mucin secretion in the
airways.
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